Thalidomide is initially promoted as a sedative, has immunomodulatory, anti-inflammatory and anti-angiogenic cancer properties, and targets cereblon (CRBN), a part of the cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, with a Kd of ∼250 nM[1].
Thalidomide waxaa markii hore loo dallacsiiyaa inuu yahay daawo dejiye ah, wuxuu leeyahay astaamo difaaca jirka ah, anti-bararka iyo anti-angiogenic, wuxuuna bartilmaameedsadaa cereblon (CRBN), qayb ka mid ah cullin-4 E3 ubiquitin ligase complex CUL4-RBX1-DDB1, oo leh Kd of ∼250 nM [1].